BioGaia Initiates Investigative Study in Type 2 Diabetics

Based on encouraging findings after supplementation of BioGaia's probiotic strain Lactobacillus reuteri Protectis in patients with type 2 diabetes in an earlier pilot study, this double-blind, placebo-controlled study will examine the effects of Lactobacillus reuteri Protectis supplementation on blood glucose control over a 12 week period.

15 May 2012 --- BioGaia has initiated an investigative study in type 2 diabetics together with Gothia Forum for Clinical Research at Sahlgrenska University Hospital in Gothenburg in collaboration with Sahlgrenska Center for Cardiovascular and Metabolic Research.

Based on encouraging findings after supplementation of BioGaia's probiotic strain Lactobacillus reuteri Protectis in patients with type 2 diabetes in an earlier pilot study, this double-blind, placebo-controlled study will examine the effects of Lactobacillus reuteri Protectis supplementation on blood glucose control over a 12 week period. The study will address both clinical outcome parameters as well as attempting to define potential mechanistic explanations for the effects seen.

“We are at an early stage in the development of products in this potentially interesting new area for BioGaia. Type 2 diabetes is a huge and growing problem all over the world,” says Peter Rothschild, BioGaia President.

BioGaia is issuing this press release, as the study will soon become public on www.clinicaltrials.gov following approval from the ethical committee and according to requirements of the company. More details regarding the study can be found on this web site.

Source: Sahlgrenska University Hospital